BioMarin's Roctavian, a hemophilia gene therapy, has hit some bumps on the road to approval, but ICER has already determined how it would be cost- ...
https://www.google.com/url?rct=j&sa=t&url=https://www.fiercepharma.com/pharma/cost-watchdog-icer-will-bless-some-high-priced-gene-and-cell-therapies-but-only-solid-proof&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw2iqfCjv8lkaWpJ4Klh_Lts
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.